RxDoctor Payments Data

Kay Kovac

Family Medicine · Lake Providence, LANPI 1326159450

Payments from drug & device makers

$791in general payments, 2019–2025

Across 35 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Venclose Inc.$242
  • Bayer$232
  • Pfizer$68
  • Lilly USA, LLC$57
  • Novo Nordisk$48
  • Mylan Specialty L.p.$37
  • plus $105 from 5 others

What the payments were for

  • Food & beverage$78499%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$791 in reported general payments places this provider in the 50th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$10,615
Medicare patients
71
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$84,231
EliquisApixaban186$79,855
JardianceEmpagliflozin91$53,838
TrulicityDulaglutide41$51,877
MounjaroTirzepatide45$49,936
LinzessLinaclotide66$37,771
NuedextaDextromethorphan Hbr/Quinidine32$31,114
Tresiba Flextouch U-200Insulin Degludec33$26,726
TradjentaLinagliptin36$22,580
XareltoRivaroxaban57$20,112
EntrestoSacubitril/Valsartan32$17,235
JanuviaSitagliptin Phosphate17$14,315
Tresiba Flextouch U-100Insulin Degludec19$12,475
FarxigaDapagliflozin Propanediol14$8,254
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$7,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$57$104,233167 claims
Novo NordiskOzempic$48$84,23181 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$16$83,877144 claims
PfizerEliquis$68$79,855186 claims
Johnson & JohnsonXarelto$37$20,11257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Providence

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →